24/7 MarketNews

Kraig Labs’ new DNA Synthesis breakthrough could unlock the Revenue Streams door

2018-08-23T18:32:30+00:00 May. 23, 2018 11:38AM EST|

Diverse Revenue Streams are the key to sustainable Biotech business models

The problem with too many biotech business models is that their revenue streams are one dimensional, in that they are often generated by one drug, but the upside is that the need to diversify revenues makes smaller biotechs very sexy acquisition targets.

The current biotech acquisition party started when Gilead Sciences (NASDAQ: GILD) announced that it was going to acquire Kite Pharma for $11.9 billion, which was followed by Celgene’s (NASDAQ: CELG) $9 billion takeover of Juno Therapeutics, and Sanofi’s (NYSE: SNY) $11.6 billion Bioverativ and $4.8 billion Ablynx double play.

Development of multiple revenue streams is so important to biotechs that Goldman Sachs (NYSE: GS) asked, in their "The Genome Revolution" report, “Is curing patients a sustainable business model?”

Kraig Biocraft Laboratories (OTCQB: KBLB), which developed what many consider to be the best spider silk fiber technology, is in the enviable position of being a small biotech company that may fill the needs of the many product developers and engineers, which, in turn, could potentially unlock multiple future revenue streams.

For a company that currently only has one revenue stream, a contract to produce customized fibers for the US Army, that may sound like a stretch, but recent developments, which include being green lighted to set up production in Vietnam, after receiving an invitation from the Vietnamese government, indicate that the Company is gearing up to carve out its portion of the $5 billion raw silk fibers market, as well as a broad cross section of applications in the $160 billion (estimated) technical fibers market and the budding smart textile markets. 

Kraig Labs’ transgenic silkworks are designed produce high performance recombinant spider silk fibers that are ecologically friendly and biocompatible.

Spider silk is said to be 10 times greater than steel, while some silks are nearly as elastic as rubber, and, according to some studies, can be two to three times tougher than even Kevlar. These eye popping properties have motivated a slew of researchers to target this fiber to be the basis for protective clothing and body armor applications, as well as other potential military applications including technical undergarments and more practical ropes.

It’s believed that spider silk may also be the foundation to many lightweight products, including air bags, seat belts, flexible bridge suspension cables, sports helmets and motor vehicle panels, as well as the next generation of medical breakthroughs, as studies have shown spider silk to be antimicrobial, biocompatible, hypoallergenic and totally biodegradable. Spider silk is a biomaterial that could be the platform on which to develop many medical technologies, like better bandages, elastic ligaments, and artificial tendons and even biodegradable water bottles.

The list of potential uses is way too long to list here, but, if you have a few spare hours, prepare to be blown away by what the eggheads are dreaming up.

The stakes are high, so today’s announcement that Kraig Labs developed new breakthrough spider silk DNA synthesis protocols, which the Company believes will accelerate the new super fibers development process, as well as reduce the R&D process costs.  The goal is to produce fibers with even greater strength and flexibility than the Company’s current recombinant spider silk offerings, for “wider applications in military and high performance technical textile markets.” 

Connect with 24/7 Market News on social media

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

24/7MN has covered Kraig Biocraft Laboratories, Inc. in the past and owns shares. You may view this as a conflict of interest. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice.   24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to www.247marketnews.com 

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan," or "planned," "will," or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements

CONTACT:

24/7 Market News

Editor@247marketnews.com

Send this to a friend

Hi, this may be interesting you: Kraig Biocraft Laboratories’ New R&D Facility Extends Its Competitive Advantages and Prepares for Large Scale Production! This is the link: https://www.247marketnews.com/kraig-biocraft-laboratories-new-rd-facility-extends-its-competitive-advantages-and-prepares-for-large-scale-production/